A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million ...
The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...
MedPage Today on MSN1d
STRIDE: Semaglutide Shows it Has Legs in Peripheral Artery DiseaseSemaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building its ...
A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million Americans over the age of 40, is ...
The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...
The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk ...
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...
Eight specific habits — diet, sleep, physical activity, smoking, body mass index, blood glucose, lipids and blood pressure — ...
A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million Americans over the age of 40, is often underdiagnosed and undertreated, with fewer ...
Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, ...
COLUMBIA SC (WOLO) – We all understand the importance of the heart, but there are some other afflictions related to the ...
STRIDE investigator Marc Bonaca, MD, MPH, University of Colorado School of Medicine, highlights how the data could provide insight into peripheral artery disease and type 2 diabetes treatment options.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback